TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03085251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring systems for self-testing (BGMS)
Description: Measurement procedure~* Subjects will be asked to wash and dry their hands before the measurements.~* The measurement procedure for each reagent system lot of a BGMS will be as follows:~* Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~* Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~* Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~* The sample will be applied to the reagent system units following specifications in the manufacturer's labelling.
Study: NCT01807871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch, experimental use
Description: nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch, labeled use
Description: nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
Study: NCT01946347

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mixed meal
Description: Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed meal
Description: Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute in vivo induced hyperinsulinemia
Description: Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute in vivo induced hyperinsulinemia
Description: Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
Study: NCT03711955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
Study: NCT00783406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: dry powder inhaler, 1472 mcg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: dry powder inhaler, 736 mcg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: dry powder inhaler, 368 mcg, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02253277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
Study: NCT02634060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Based Fecal Calprotectin
Description: Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
Study: NCT00600795

Intervention type: OTHER
Intervention: CSF collection
Description: CSF collection at time of VPS insertion
Study: NCT02158936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous Injection (IV if local standard)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Subcutaneous Injection (IV if local standard)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eltrombopag matching placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eltrombopag matching placebo tablets will be supplied
Study: NCT01943071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day care for patients with dementia
Description: Day care centres designed by the local authorities for patients with dementia
Study: NCT03966170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citicoline as neuroprotector

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo drug
Study: NCT04253431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Droplet lancing device (HTL-Strefa S.A.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Droplet lancing device (HTL-Strefa S.A.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Droplet lancing device (HTL-Strefa S.A.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlet 2 lancing device (Bayer)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microlet 2 lancing device (Bayer)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Delicia lancing device (LifeScan)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReliOn lancing device (ReliOn)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Softclix lancing device (Roche)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGStar lancing device (Sanofi Aventis)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra-Fine 33G lancets (BD)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Droplet 33G lancets (HTL-Strefa S.A.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Droplet 33G lancets (HTL-Strefa S.A.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Delicia Extra Fine 33G lancets (LifeScan)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HaemoFine 33G lancets (HTL-Strefa S.A.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HaemoFine 33G lancets (HTL-Strefa S.A.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Softclix 28 G lancets (Roche)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReliOn Ultra-Thin Plus 33G lancets (ReliOn)
Study: NCT01585350

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MELITAC 12.1 + Montanide ISA-51 + polyICLC
Description: Cohort 2 will be divided into three sub-groups and will receive:~* Group 2a: MELITAC 12.1 + polyICLC adjuvant~* Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~* Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations
Study: NCT01759810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes
Study: NCT01756781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Treatment B includes 8 daily 125 mg oral doses of PD-0332991.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
Study: NCT04781829

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BioFire Pneumonia Panel
Description: Treatment based on an algorithm that recommends antibiotic choices based on bacteria/virus detected by BioFire Pneumonia Panel
Study: NCT02707406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEOX®CORD 1K
Description: use of human tissue product wound covering

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Description: standard wound coverings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: standard wound coverings
Study: NCT03119623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan
Description: Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: enalapril 5mg, titrated up to 10mg po BID
Study: NCT03811288

Intervention type: OTHER
Intervention: No treatment given
Description: No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
Study: NCT04161079

Intervention type: DEVICE
Intervention: Medtentia Annuloplasty Ring (MAR)
Description: Mitral valve repair using the MAR performed in clinical investigation 2010-040
Study: NCT01985438

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous endoscopic gastrostomy tube placement
Description: A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube placement
Description: All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
Study: NCT03615716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level Violence Prevention Intervention - Boys
Description: Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level Violence Prevention Intervention - Caregivers
Description: This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
Study: NCT04291482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choosing Health Intervention
Description: The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Choosing Health Control
Description: The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
Study: NCT00616980

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CD34-positive cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CD34-positive cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline and 5% autologous plasma
Study: NCT01329718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Blood sample collection
Study: NCT03873909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit Smoothie
Description: Fruit Smoothie with 150-200 g mamey sapote fruit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-Free Shake
Description: Shake containing mamey sapote extracted carotenoids (2 g, 845 µg sapotexanthin and 1.21-1.51 mg cryptocapsin
Study: NCT01841450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of one iStent in conjunction with cataract surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery alone
Study: NCT04655040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 100milligram (mg) tablet taken orally in period 1 and period 2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: 200 milligrams (mg) taken orally once a day(QD) for 8 days
Study: NCT03273400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Mobilisations
Description: Please see arm (intervention) description
Study: NCT02438605

Intervention type: DEVICE
Intervention: Nellix
Study: NCT03361865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.
Study: NCT01700348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airflosser
Description: Use of Philips Airflosser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Floss
Description: Active Comparator
Study: NCT00214032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Description: pycnogenol 300 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 3 capsules daily
Study: NCT03449537

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed casein formula + LGG
Description: Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
Study: NCT03361865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally twice daily.
Study: NCT00176644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed.
Study: NCT03443310

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound assessment of DVT
Description: Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
Study: NCT02395263

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yuxintine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yuxintine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yuxintine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yuxintine
Study: NCT04159649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5Mg Tablet
Description: Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropins
Description: Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial sample in the pretreatment cycle
Description: All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial sample in the pretreatment cycle
Description: All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
Study: NCT03652233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by vein every 14 days for up to 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Taken by mouth daily for up to 12 months
Study: NCT01967641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone combination
Description: Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
Study: NCT03370575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethiodized poppyseed oil
Description: Hysterosalpingography using ethiodized poppyseed oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the second-generation non-ionic monomer contrast
Description: Hysterosalpingography using the second-generation non-ionic monomer contrast
Study: NCT01518231

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoiesis stem cell transplantation
Description: Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: aspirin 100mg,qd,po(patients with no fibrillation atrial)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: warfarin 2\~6mg,qd,po(patients with fibrillation atrial);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 20mg,qd,po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: edaravone 30mg,bid,ivgtt.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Aspirin
Description: aspirin 100mg,qd,po(patients with no fibrillation atrial)

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Warfarin
Description: warfarin 2\~6mg,qd,po(patients with fibrillation atrial)

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atorvastatin
Description: atorvastatin 20mg,qd,po

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Edaravone
Description: edaravone 30mg,bid,ivgtt
Study: NCT01253668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate
Description: Brivanib by mouth daily at a dose of 800mg.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction
Description: Undergo 1241-cG250 PET/CT imaging (correlative studies)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine I 124 chimeric monoclonal antibody G250
Description: Undergo 124I-cG250 PET/CT imaging (correlative studies)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography
Description: Undergo 1241-cG250 PET/CT imaging (correlative studies)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Protein expression analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Description: correlative studies
Study: NCT03449537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypoallergenic formula based on amino-acid based formula
Description: Hypoallergenic formula for cow milk allergy treatment based on amino acids